The Expanding Picture of the Clinical Utility of BEPREVE® (Bepotastine Besilate Ophthalmic Solution) 1.5 % in the Treatment of Itch Associated with Allergic Conjunctivitis

2011 ◽  
Vol 04 (02) ◽  
pp. 101
Author(s):  
Richard L Lindstrom ◽  
Keyword(s):  
Allergic Conjunctivitis ◽  
Clinical Utility ◽  
Therapeutic Response ◽  
Ophthalmic Solution ◽  
Trial Data ◽  
Ocular Allergy ◽  
Pivotal Trial ◽  
Exposure Study ◽  
Fda Approval ◽  
Ocular Itching

A new analysis of pivotal trial data and a variety of additional studies completed since US Food and Drug Administration (FDA) approval are broadening our understanding of the clinical utility of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5 % in the treatment of ocular itch associated with allergic conjunctivitis. These results include evidence of a durable therapeutic response of up to 16 hours following a single dose, a comfort profile comparable or superior to other drugs in the class, and robust efficacy against ocular itching and redness in an environmental exposure study model that simulates the patient experience of ocular allergy.

scholarly journals Evaluating Clinical Perceptions of a New Medication for Ocular Itch Associated with Allergic Conjunctivitis—Results of the Bepreve® 1.5% First Experience Field Survey

2011 ◽  
Vol 04 (01) ◽  
pp. 69
Author(s):  
Jai G Parekh ◽  
Keyword(s):  
Clinical Trial ◽  
Survey Data ◽  
Allergic Conjunctivitis ◽  
Field Survey ◽  
Ophthalmic Solution ◽  
Patient Experiences ◽  
Ocular Allergy ◽  
Over The Counter ◽  
Professional Evaluation ◽  
Clinical Trial Results

Allergic conjunctivitis associated with seasonal or perennial allergy is an increasingly prevalent complaint. Patients seeking professional evaluation for symptoms of ocular allergy usually have exhausted over-the-counter options and expect rapid, effective relief from the treatment prescribed. With the introduction of Bepreve® (bepotastine besilate ophthalmic solution) 1.5%, a survey of US doctors was conducted to evaluate their opinions and impressions of the medication following the initial patient trial. Responses from 427 practitioners, representing a total of 7,340 patient experiences, suggest that Bepreve is a rapidly effective and comfortable treatment. Nearly all respondents reported being satisfied or very satisfied with the performance of Bepreve. These survey data from the office setting are consistent with clinical trial results demonstrating that Bepreve provides rapid, durable, and comfortable relief of ocular itch.

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

2012 ◽  
Vol 33 (3) ◽  
pp. 265-274 ◽  
Author(s):  
Edward J. Meier ◽  
Gail L. Torkildsen ◽  
James A. Gow ◽  
Timothy R. McNamara ◽  
Paul J. Gomes ◽  
...  
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Ocular Itching ◽  
Phase Iii Trials

Allergic inflammation of the anterior surface of the eye

2020 ◽  
Vol 41 (6) ◽  
pp. 449-453 ◽  
Author(s):  
Leonard Bielory
Keyword(s):  
Allergic Conjunctivitis ◽  
Allergic Inflammation ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Histamine Receptor ◽  
Oral Medications ◽  
Ocular Itching ◽  
Repurposed Drugs ◽  
New Treatments ◽  
H1 Receptor Antagonist

Background: Ocular allergies affect an estimated 40% of the population, 98% of which are because of allergic conjunctivitis and includes tear film dysfunction. With the current advent of both repurposed drugs for ocular allergies, as well as novel drugs, lubricants and methods of administration, there is a need to update new treatments to optimize the care of ocular allergy patients. Methods: An overview of mediators, clinical characteristics and management is provided in a summary format. Results: Lubricants (best when refrigerated provide immediate relief that is short lived (several minutes) due to its dilutional effect on mediators and pollen in the tear film. Immediate and longer-term benefit occurs from different topical and oral medications ‐ primarily histamine receptor agonists. Conclusion: The newest prescription topical ophthalmic histamine H1 receptor antagonist (an inverse agonist) to be approved by the U.S. Food and Drug Administration in the past 10 years (U.S. NDA approved May 30, 2017) is cetirizine ophthalmic solution for the treatment of ocular itching with allergic conjunctivitis in adults and in children more than 2 years old.

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

2009 ◽  
Vol 123 (2) ◽  
pp. S57-S57 ◽  
Author(s):  
G.L. Torkildsen ◽  
P.J. Gomes ◽  
J.I. Williams ◽  
J.A. Gow ◽  
T.R. McNamara
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Clinical Model ◽  
Ocular Itching

scholarly journals Allergic conjunctivitis in a tertiary eye hospital, Nigeria

2015 ◽  
Vol 3 (4) ◽  
pp. 149-152
Author(s):  
Monsudi Kehinde Fasasi ◽  
Ayanniyi Ayansiji Abdul Kabir ◽  
Balarabe Aliyu Hamza ◽  
Azonobi Ifeanyi Richard ◽  
Saka Eletu Sadiat ◽  
...  
Keyword(s):  
Allergic Conjunctivitis ◽  
Age Groups ◽  
Care Facility ◽  
Allergic Diseases ◽  
Cross Sectional Study ◽  
Ocular Allergy ◽  
Cross Sectional ◽  
Ocular Itching ◽  
Allergic Condition ◽  
History Of

Background: Worldwide, approximately 1/3 of the populations are affected by allergic diseases. Ocular allergy symptoms presented in 40-80% of the affected individuals. Allergic eye disease is a localized allergic condition that is frequently associated with rhinitis and occasionally with asthma. The symptoms and signs can manifest as conjunctivitis, blepharitis, blepharoconjunctivitis, or keratoconjunctivitis.Objective: To determine the pattern of presentation of ocular allergy in the study population and to create awareness among health professional and the public.Methods: A four months hospital based cross sectional study involving administration of self explained structured questionnaires to all consented patients that presented at our eye care facility on accounts of ocular itching during the study period was conducted. All the patients had comprehensive eye assessment by consultant ophthalmologist. Data was analyzed with SPSS version 18Results: Of 200 patients that presented with conjunctivitis during the study period 163 (82%) patients were due to allergic conjunctivitis. There were 80 males and 83 females. Majority (43.6%) of the patients were within the age groups of 17 years-33 years, followed by 0-16 years (42.3%). Majority of the patients 102 (62.3%) presented with symptoms of ocular itching and redness. Only 18 (11%) of the patients were a known asthmatic. However, 73 (44.8%), 87 (53.4%) and 79 (48.5%) of these patients have family history of asthma, atopy and ocular allergy respectively. Most of the patients 161 (98.8%) were treated with medication, while only two patients had surgical intervention (cornea ulcer debridement).Conclusion: Allergic conjunctivitis is the commonest reasons why patients present with conjunctivitis at our eye clinic and it is commonest in the active age group. Eye health education about ocular allergy is underscored.Journal of Kathmandu Medical CollegeVol. 3, No. 4, 2014Page: 149-152

Sign in / Sign up

Export Citation Format

Share Document